조직 진단 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 제품별, 용도별, 기술별, 지역별 경쟁(2021-2031년)

The Global Tissue Diagnostics Market is set for substantial expansion, with projections indicating growth from USD 5.83 Billion in 2025 to USD 9.56 Billion by 2031, at an impressive CAGR of 8.59%. This market segment focuses on the extraction and meticulous analysis of biological tissue samples to identify and diagnose various diseases, most notably cancer. Key growth catalysts include the increasing global prevalence of oncology cases and an aging worldwide population that frequently requires medical interventions. Furthermore, the growing emphasis on personalized healthcare is stimulating demand for precise biomarker analysis, which is crucial for tailoring effective therapeutic strategies. For instance, the American Cancer Society estimates that approximately 2,041,910 new cancer cases will be diagnosed in the United States in 2025, underscoring the escalating demand for advanced diagnostic infrastructure.

However, a significant impediment to the market's expansion is the scarcity of skilled pathologists and laboratory professionals, who are vital for interpreting complex tissue samples accurately. This workforce deficiency directly limits diagnostic throughput and extends turnaround times, creating a critical bottleneck that hinders the broader adoption and implementation of advanced tissue diagnostic solutions across healthcare systems globally.

Market Driver

The primary force driving the Global Tissue Diagnostics Market is the escalating worldwide prevalence of cancer and various chronic diseases. As the burden of oncology cases intensifies, there is a commensurate surge in the volume of tissue biopsies needed for definitive diagnosis and accurate staging. This demand is further exacerbated by the aging global demographic, which inherently faces higher susceptibility to cellular mutations and chronic conditions requiring detailed histopathological examination. A study by The Lancet in September 2025 projected that new global cancer cases will exceed 30 million annually by 2050, highlighting the urgent need for scalable diagnostic capabilities. This increasing caseload necessitates robust tissue processing, advanced staining workflows, and high-throughput platforms to effectively manage patient samples and facilitate timely therapeutic decisions.

Simultaneously, the integration of artificial intelligence (AI) and digital pathology solutions is transforming market dynamics by significantly enhancing diagnostic precision and optimizing workflow efficiency. Laboratories are increasingly adopting automated scanning and AI algorithms to assist pathologists in identifying subtle morphological patterns, thereby minimizing human error and alleviating workload pressures exacerbated by workforce shortages. According to CAP TODAY in September 2025, the adoption rate of digital pathology within United States diagnostic practices has reached 15-20%, indicating a clear shift from traditional microscopy to digitized operations. This technological evolution is strongly supported by sustained investment in healthcare research, with the National Cancer Institute requesting approximately $7.8 billion in 2025 to fund extensive cancer research and infrastructure development, fostering an environment conducive to continued diagnostic innovation.

Market Challenge

The critical shortage of skilled pathologists and laboratory professionals poses a substantial obstacle to the growth of the Global Tissue Diagnostics Market. Since expert interpretation is indispensable for identifying complex disease markers in tissue analysis, an insufficient number of qualified personnel invariably creates a significant operational bottleneck. When anatomic pathology departments are understaffed, diagnostic throughput slows considerably, leading to delayed patient reports and an inability to process surging case volumes. This operational constraint directly impacts market revenue by preventing diagnostic service providers from scaling their output to meet the intensifying clinical demand.

Emphasizing the severity of this workforce deficit, the American Society for Clinical Pathology reported in 2025 that anatomic pathology departments exhibited the highest overall vacancy rate among laboratory sectors at 28.5%. This statistic reveals that nearly one-third of the crucial positions required for tissue diagnostics remain unfilled. Such a profound scarcity effectively limits the adoption of high-volume testing and advanced biomarker analyses, ultimately capping the market's potential expansion as healthcare systems struggle to bridge the gap between diagnostic requirements and available expert resources.

Market Trends

The expansion of tissue-based companion diagnostics for precision oncology is fundamentally reshaping the market, driven by pharmaceutical collaborations focused on developing assays essential for targeted therapies. This trend signifies a strategic pivot from merely detecting disease presence to precisely identifying specific molecular targets, which necessitates high-precision immunohistochemistry and in situ hybridization tools. Diagnostic providers are increasingly generating revenue through co-development agreements that directly link particular tissue biomarkers to immune checkpoint inhibitors and other targeted drugs. Highlighting the financial impact of this growing demand, Agilent Technologies reported in November 2025 that its Life Sciences and Diagnostics Markets Group achieved $755 million in revenue for the fourth-quarter fiscal year 2025, marking a 15% year-over-year increase largely fueled by momentum in diagnostic partnerships.

Concurrently, the emergence of spatial biology is empowering researchers by enabling the mapping of cellular interactions within the tumor microenvironment without compromising the original tissue architecture. Unlike traditional bulk sequencing methods, this innovative approach preserves the spatial context of both immune and tumor cells, which is vital for comprehensively understanding mechanisms of drug resistance and immune evasion. The rapid scientific validation of these platforms is evident in their widespread adoption for both translational research and complex tissue profiling. According to Akoya Biosciences' May 2025 'First Quarter 2025 Financial Results', the cumulative number of publications citing the company's spatial biology technology reached 1,891, representing a significant 44.7% increase compared to the previous year.

Key Market Players

• Nanoscribe GmbH & Co. KG
• Stratasys Ltd.
• 3D Systems Inc.
• EOS GmbH
• Renishaw PLC
• Exone Company.
• Formlabs Inc.,
• Materialise NV.
• SLM Solutions Group AG
• Oxferd Performance Materials, Inc.

Report Scope

In this report, the Global Tissue Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue Diagnostics Market, By Product

• Instruments
• Reagents
• Consumables

Tissue Diagnostics Market, By Application

• Breast Cancer
• Prostate Cancer
• Gastric Cancer
• Other Cancers

Tissue Diagnostics Market, By Technology

• Immunohistochemistry
• In-Situ Hybridizations
• Digital Pathology and Workflow Management
• Others

Tissue Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue Diagnostics Market.

Available Customizations:

Global Tissue Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Reagents, Consumables)
  • 5.2.2. By Application (Breast Cancer, Prostate Cancer, Gastric Cancer, Other Cancers)
  • 5.2.3. By Technology (Immunohistochemistry, In-Situ Hybridizations, Digital Pathology and Workflow Management, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Tissue Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tissue Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
  • 6.3.2. Canada Tissue Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
  • 6.3.3. Mexico Tissue Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology

7. Europe Tissue Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tissue Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
  • 7.3.2. France Tissue Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
  • 7.3.3. United Kingdom Tissue Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology
  • 7.3.4. Italy Tissue Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technology
  • 7.3.5. Spain Tissue Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technology

8. Asia Pacific Tissue Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tissue Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
  • 8.3.2. India Tissue Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
  • 8.3.3. Japan Tissue Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology
  • 8.3.4. South Korea Tissue Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technology
  • 8.3.5. Australia Tissue Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technology

9. Middle East & Africa Tissue Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tissue Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
  • 9.3.2. UAE Tissue Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
  • 9.3.3. South Africa Tissue Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology

10. South America Tissue Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technology
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tissue Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technology
  • 10.3.2. Colombia Tissue Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technology
  • 10.3.3. Argentina Tissue Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technology

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tissue Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Nanoscribe GmbH & Co. KG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Stratasys Ltd.
• 15.3. 3D Systems Inc.
• 15.4. EOS GmbH
• 15.5. Renishaw PLC
• 15.6. Exone Company.
• 15.7. Formlabs Inc.,
• 15.8. Materialise NV.
• 15.9. SLM Solutions Group AG
• 15.10. Oxferd Performance Materials, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer